PT1185649E - Promotor do gene da miostatina e inibicao da sua activacao - Google Patents

Promotor do gene da miostatina e inibicao da sua activacao

Info

Publication number
PT1185649E
PT1185649E PT00941296T PT00941296T PT1185649E PT 1185649 E PT1185649 E PT 1185649E PT 00941296 T PT00941296 T PT 00941296T PT 00941296 T PT00941296 T PT 00941296T PT 1185649 E PT1185649 E PT 1185649E
Authority
PT
Portugal
Prior art keywords
promoter
gene
miostatina
initiation
activation
Prior art date
Application number
PT00941296T
Other languages
English (en)
Inventor
Jinshyun R Wu-Wong
Wang Jiahong
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PT1185649E publication Critical patent/PT1185649E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT00941296T 1999-06-10 2000-06-09 Promotor do gene da miostatina e inibicao da sua activacao PT1185649E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/329,685 US6284882B1 (en) 1999-06-10 1999-06-10 Myostatin gene promoter and inhibition of activation thereof

Publications (1)

Publication Number Publication Date
PT1185649E true PT1185649E (pt) 2005-08-31

Family

ID=23286552

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00941296T PT1185649E (pt) 1999-06-10 2000-06-09 Promotor do gene da miostatina e inibicao da sua activacao

Country Status (10)

Country Link
US (2) US6284882B1 (pt)
EP (1) EP1185649B1 (pt)
JP (1) JP4625602B2 (pt)
AT (1) ATE293691T1 (pt)
CA (1) CA2375820C (pt)
DE (1) DE60019586T2 (pt)
ES (1) ES2240108T3 (pt)
MX (1) MXPA01012665A (pt)
PT (1) PT1185649E (pt)
WO (1) WO2000077206A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555672B1 (en) * 1998-07-15 2003-04-29 Metamorphix, Inc. Growth differentiation factor promoter and uses therefor
ZA200003786B (en) * 1999-07-30 2002-01-21 Pfizer Prod Inc Myostatin regulatory region, nucleotide sequence determination and methods for its use.
EP1404866B1 (en) * 2001-07-11 2008-09-03 ORICO Limited Bioassay for myostatin
KR20130036378A (ko) * 2002-12-20 2013-04-11 암겐 인코포레이티드 미오스타틴을 저해하는 결합제
US8426194B2 (en) * 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
US9068234B2 (en) * 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
EP1604011A4 (en) 2003-01-21 2009-12-09 Ptc Therapeutics Inc METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE THE EXPRESSION OF DEPENDENT GENES FROM A NON-TRANSLATED REGION, AND METHODS OF USING SAME
RU2422460C2 (ru) * 2003-12-31 2011-06-27 Шеринг-Плоу Лтд. Выделенный пептид, обладающий специфической связывающей анти-gdf-8 антитело активностью, выделенная молекула нуклеиновой кислоты, вектор экспрессии, клетка-хозяин, способ получения пептида, вакцинная композиция и способ вызывания иммунного ответа анти-gdf-8, способ скрининга для отбора анти-gdf-8 антитела и способ понижающего регулирования активности gdf-8 у животного
ES2679282T3 (es) 2004-10-22 2018-08-23 Revivicor Inc. Porcinos transgénicos que carecen de cadena ligera de inmunoglobulina endógena
AR051853A1 (es) 2004-12-30 2007-02-14 Schering Plough Ltd Vacuna para aumentar el crecimiento basada en epitopes neutralizantes
ES2852549T3 (es) 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
CN101147068A (zh) * 2005-03-23 2008-03-19 惠氏公司 Gdf-8调节剂的检测
US20060240488A1 (en) * 2005-03-23 2006-10-26 Nowak John A Detection of an immune response to GDF-8 modulating agents
CA2538208A1 (en) * 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
CA2632544C (en) * 2005-12-06 2014-09-23 Amgen Inc. Use of myostatin antagonist for treating the effects of hypogonadism
US8426374B1 (en) 2006-05-04 2013-04-23 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Method for modifying myostatin expression
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
NZ584848A (en) 2007-09-28 2012-09-28 Intrexon Corp Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
DK2348827T3 (en) 2008-10-27 2015-07-20 Revivicor Inc IMMUNICIPLY COMPROMATED PETS
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
EA201890908A1 (ru) 2015-10-09 2018-10-31 Сарепта Терапьютикс, Инк. Композиции и способы для лечения мышечной дистрофии дюшенна и сходных нарушений

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2201076T3 (es) * 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 de diferenciacion del crecimiento.
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
AU6274298A (en) * 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
US6555672B1 (en) * 1998-07-15 2003-04-29 Metamorphix, Inc. Growth differentiation factor promoter and uses therefor
ZA200003786B (en) 1999-07-30 2002-01-21 Pfizer Prod Inc Myostatin regulatory region, nucleotide sequence determination and methods for its use.

Also Published As

Publication number Publication date
CA2375820C (en) 2010-07-27
EP1185649B1 (en) 2005-04-20
JP2003528574A (ja) 2003-09-30
DE60019586D1 (de) 2005-05-25
ATE293691T1 (de) 2005-05-15
MXPA01012665A (es) 2002-07-22
US6399312B2 (en) 2002-06-04
US20010049435A1 (en) 2001-12-06
CA2375820A1 (en) 2000-12-21
US6284882B1 (en) 2001-09-04
WO2000077206A2 (en) 2000-12-21
WO2000077206A3 (en) 2001-12-06
ES2240108T3 (es) 2005-10-16
EP1185649A2 (en) 2002-03-13
JP4625602B2 (ja) 2011-02-02
DE60019586T2 (de) 2006-03-09

Similar Documents

Publication Publication Date Title
PT1185649E (pt) Promotor do gene da miostatina e inibicao da sua activacao
ATE244717T1 (de) Inhibitoren des impdh-enzyms
TR199902545T2 (xx) Kalp damar hastal�klar�n�n �nlenmesinde siklooksijenaz-2 inhibit�rlerini kullanma y�ntemi
PL402389A1 (pl) Sposób hamowania aktywnosci kinazy Raf u ludzi lub zwierzat
ECSP034603A (es) Combinaciones sinergicas que comprenden un inhibidor de renina para enfermedades cardiovasculares
NO995544D0 (no) Forbindelser og metoder for inhibering av ekspresjonen av VCAM-1
AU3652102A (en) Compounds and their uses
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
EP1446136A4 (en) CURCUMINOID COMPOSITIONS WITH SYNERGISTIC INHIBITION OF EXPRESSION AND / OR EFFECT OF CYCLOOXYGENASE-2
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
DE69840603D1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
PT1250340E (pt) Metodos e compostos para inibicao de mrp1
WO2001056573A8 (en) Use of cox-2 inhibitors as gastroprokinetics
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
EP1244452A4 (en) UROTENSIN II RECEPTOR ANTAGONISTS
NO996287D0 (no) Chalkoner med antiproliferativ aktivitet
DE60329326D1 (de) Tace inhibitoren
EA200100930A1 (ru) Способ лечения хозл
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
WO2004060878A3 (en) Inhibitors of phosphatases
ATE305517T1 (de) Neurotrypsin
BR0111785A (pt) Composições e métodos para tratamento de candidìase
PT1276722E (pt) Inibidores de naftamidina-uroquinase